Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

Merck and Ridgeback Biotherapeutics withdrew their COVID-19 pill application in the European Union due to insufficient data for not backing the drug. Additionally, a recent study featured in the ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a deal that adds to a surge of industry interest in using so-called bispecific antibodies ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

Merck stock was falling. Rival Summit Therapeutics said its cancer drug Ivonescimab reduced the risk of disease progression ...

EMD Serono Inc., Merck KGaA’s North American drug development business ... Vertex Pharmaceuticals Inc. recently extended its ...

AIDDISON is Merck’s AI-powered drug discovery platform that integrates ... For instance, during the critical periods of the coronavirus disease 2019 (COVID-19) pandemic, Syntropy played a ...

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...